Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 02, 2025 08:45 ET | Source: International Myeloma Foundation

The International Myeloma Foundation Proudly Announces EMA-CHMP Positive Qualification Advice to i2TEAMM Novel Biomarker Procedure Application on the Use of MRDnegCR as an Intermediate Early Endpoint for Conditional Market Approval in Myeloma Clinical Trials

STUDIO CITY, Calif., July 02, 2025 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) and the collaborative stakeholder group i2TEAMM (International Independent Team for Endpoint...
October 18, 2023 08:30 ET | Source: Imunon, Inc.

IMUNON Announces First Patient enrolled in Phase 1/2 Clinical Trial of IMNN-001 in Combination with bevacizumab in Advanced Ovarian Cancer

The MRD trial will evaluate the effect of this treatment combination on minimal residual disease. LAWRENCEVILLE, N.J., Oct. 18, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a...
September 14, 2023 09:51 ET | Source: Emergen Research

Global Minimal Residual Disease (MRD) Market Size to Reach USD 4,138.5 Million in 2030 | Emergen Research

Vancouver, Sept. 14, 2023 (GLOBE NEWSWIRE) -- The global Minimal Residual Disease (MRD) market size was USD 1,095.3 Million in 2021 and is expected to register a revenue CAGR of 16.04% during the...
August 03, 2023 08:30 ET | Source: MarketsandMarkets Research Pvt. Ltd.

Minimal Residual Disease Testing Market is Expected to Reach $2.3 Billion | MarketsandMarkets.

Chicago, Aug. 03, 2023 (GLOBE NEWSWIRE) -- In the near future, the Minimal Residual Disease (MRD) testing industry is poised to experience remarkable growth and transformative advancements. As...
May 21, 2019 06:00 ET | Source: Invivoscribe, Inc.

Invivoscribe Expanding Clinical Laboratory Network Space and Testing Capabilities in San Diego, Germany, Japan, and China. Offering Comprehensive Standardized Testing for All Hematologic Malignancies

SAN DIEGO, May 21, 2019 (GLOBE NEWSWIRE) -- Invivoscribe, Inc., a vertically integrated global company focused on Improving Lives with Precision Diagnostics®, today announces expansion of space and...
June 28, 2018 08:00 ET | Source: Actinium Pharmaceuticals

Actinium Announces New Clinical Trial to Study Effect of Actimab-A on Minimal Residual Disease in Postremission AML Patients

Minimal Residual Disease is increasingly recognized as a primary driver of high AML relapse rate highlighting need for improved consolidation therapies Webcast to be held on July 10, 2018 at 8:00 AM...